Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Christopher Pleyer, MD, Jeffrey Cohen, MD, Susan Soto, Mir Ali, PhD, Inhye E Ahn, MD, Pia Nierman, BSN, MA, RN, Janet Valdez, Jennifer Lotter, PA-C, Jeanine Superata, RN, Xin Tian, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3053.

https://doi.org/10.1182/blood-2019-121675

Published: 2019

Journal Articles

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood (2019) 134 (Supplement_1): 5474.

https://doi.org/10.1182/blood-2019-126698

Published: 2019

Journal Articles

A Novel Proteomic Profiling of the Bone Marrow Microenvironment Reveals Elevated Levels of the Chemokine CCL23 Isoforms in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 2709.

https://doi.org/10.1182/blood-2019-122121

Published: 2019

Journal Articles

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Thomas Winkler, Xing Fan, James Cooper, Ronan Desmond, David J. Young, Danielle M. Townsley, Phillip Scheinberg, Sophia Grasmeder, Andre Larochelle, Marie Desierto, Janet Valdez, Jennifer Lotter, Colin Wu, Ruba N. Shalhoub, Katherine R. Calvo, Neal S. Young, Cynthia E. Dunbar

Blood (2019) 133 (24): 2575–2585.

https://doi.org/10.1182/blood.2019000478

Published: 2019

Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2018-99-110395

Published: 2018

Journal Articles

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Xing Fan, MD, Thomas Winkler, MD, Ronan Desmond, MD, Bogdan Dumitriu, MD, Danielle M. Townsley, MD MSc, Maria del Pilar Fernandez Ibanez, Fernanda Gutierrez-Rodrigues, PhD, Sophia Grasmeder, RN, Ma Evette Barranta, Diane Madey, Jennifer Lotter, Janet Valdez, Katherine R. Calvo, MD PhD, Colin Wu, PhD, Neal S. Young, MD, Cynthia E. Dunbar, MD

Blood (2018) 132 (Supplement 1): 538.

https://doi.org/10.1182/blood-2018-99-112994

Published: 2018

Journal Articles

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Katherine E Lindblad, Julie Thompson, RN, Gege Gui, MS, Janet Valdez, Tatyana Worthy, Hanna Tekleab, Tom Hughes, Pharm.D., Meghali Goswami, BS, Karolyn Oetjen, MD, Dong-Yun Kim, PhD, Laura Dillon, PhD, Christin DeStefano, MD, Catherine E. Lai, MD, Christopher S. Hourigan, DPhil FACP FRCP

Blood (2018) 132 (Supplement 1): 1437.

https://doi.org/10.1182/blood-2018-99-115097

Published: 2018

Journal Articles

Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Christopher Pleyer, MD, Clare C. Sun, MD, Pia Niermann, Xin Tian, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Raquel Izumi, PhD, Ahmed Hamdy, MD, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2018-99-111919

Published: 2018

Journal Articles

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Blood (2018) 131 (21): 2357–2366.

https://doi.org/10.1182/blood-2017-12-820910

Published: 2018

Includes: Supplemental data

Journal Articles

Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study

Inhye E. Ahn, MD, Susan Soto, Pia Nierman, Xin Tian, PhD, Janet Valdez, Jennifer Lotter, Thomas Fleisher, Sergio Rosenzweig, Shakuntala Rampertaap, Irina Maric, Maryalice Stetler-Stevenson, Constance Yuan, Gerald Marti, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 3020.

https://doi.org/10.1182/blood.V130.Suppl_1.3020.3020

Published: 2017

Journal Articles

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Inhye E. Ahn, MD, Xin Tian, PhD, Jennifer Lotter, Susan Soto, Janet Valdez, Pia Nierman, Maryalice stetler-Stevenson, Constance Yuan, Irina Maric, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 4302.

https://doi.org/10.1182/blood.V130.Suppl_1.4302.4302

Published: 2017

Journal Articles

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Blood (2017) 129 (11): 1469–1479.

https://doi.org/10.1182/blood-2016-06-719294

Published: 2017

Includes: Supplemental data

Journal Articles

Myeloid Neoplasm Gene Somatic Mutations in Patients with Severe Aplastic Anemia Treated with Eltrombopag and Standard Immunosuppression

Danielle M. Townsley, MD, James N. Cooper, MD, Thomas Winkler, MD, Phillip Scheinberg, MD, Olga Rios, RN, Barbara Weinstein, RN, Janet Valdez, Jennifer Lotter, Marie J. Desierto, BS, Maria del Pilar Fernandez Ibanez, MS, Colin Wu, PhD, Cynthia E. Dunbar, MD, Wanlong Ma, BS, Maher Albitar, MD, Neal S. Young

Blood (2016) 128 (22): 727.

https://doi.org/10.1182/blood.V128.22.727.727

Published: 2016

Journal Articles

Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib

Inhye E Ahn, MD, Xin Tian, Susan Soto, Janet Valdez, Jennifer Lotter, Mohammed Farooqui, Adrian Wiestner, MD PhD

Blood (2016) 128 (22): 187.

https://doi.org/10.1182/blood.V128.22.187.187

Published: 2016

Journal Articles

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Francine Thomas, BS, Xin Tian, PhD, Irina Maric, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2937.

https://doi.org/10.1182/blood.V126.23.2937.2937

Published: 2015

Journal Articles

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates

Danielle M. Townsley, MD, Bogdan Dumitriu, MD, Phillip Scheinberg, MD, Ronan Desmond, MD, FRCPath, Xingmin Feng, PhD, Olga Rios, RN, Barbara Weinstein, RN, Janet Valdez, PA-C, Thomas Winkler, MD, Marie Desierto, BS, Harshraj Leuva, MBBS, Colin Wu, PhD, Katherine R. Calvo, MD, PhD, Andre Larochelle, MD, PhD, Cynthia E. Dunbar, MD, Neal S. Young, MD

Blood (2015) 126 (23): LBA-2.

https://doi.org/10.1182/blood.V126.23.LBA-2.LBA-2

Published: 2015

Journal Articles

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Amanda Bray, RN, Xin Tian, PhD, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2933.

https://doi.org/10.1182/blood.V126.23.2933.2933

Published: 2015

Journal Articles

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

Clare Sun, Xin Tian, Yuh Shan Lee, Sreenivasulu Gunti, Andrew Lipsky, Sarah E. M. Herman, Dalia Salem, Maryalice Stetler-Stevenson, Constance Yuan, Lela Kardava, Susan Moir, Irina Maric, Janet Valdez, Susan Soto, Gerald E. Marti, Mohammed Z. Farooqui, Abner L. Notkins, Adrian Wiestner, Georg Aue

Blood (2015) 126 (19): 2213–2219.

https://doi.org/10.1182/blood-2015-04-639203

Published: 2015

Includes: Supplemental data

Journal Articles

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Georg Aue, MD, Mohammed Farooqui, DO, Jade Jones, Janet Valdez, PA, Sabrina E. Martyr, MD, Susan Soto, RN, Maryalice Stetler-Stevenson, MD, PhD, Constance Yuan, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 4182.

https://doi.org/10.1182/blood.V122.21.4182.4182

Published: 2013

Journal Articles

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Sarah E. M. Herman, PhD, Rashida Z Mustafa, BS, Sabrina E. Martyr, MD, Jennifer Gyamfi, MS, Janet Valdez, PA, Susan Soto, RN, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 118.

https://doi.org/10.1182/blood.V122.21.118.118

Published: 2013

NARROW

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

A Novel Proteomic Profiling of the Bone Marrow Microenvironment Reveals Elevated Levels of the Chemokine CCL23 Isoforms in Acute Myeloid Leukemia

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Myeloid Neoplasm Gene Somatic Mutations in Patients with Severe Aplastic Anemia Treated with Eltrombopag and Standard Immunosuppression

Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only